


The Challenge

Knee OA (KOA) is a major clinical and economic burden to the NHS which effects 8.75 million adults over 45 years of age¹. Total knee replacements (TKR) are considered an effective treatment for end-stage knee OA, with 132,000 undertaken in England in 2023². However, TKR are associated with risks, complications³ and long waiting lists. There is also insufficient evidence for NICE to routinely recommend standard conservative managements options and alternatives such as insoles, supports, knee braces or intra-articular injections⁴


Apos Health



The Apos Health shoe is a NICE recommended⁵ medical device, clinically proven to reduce KOA pain. Modelled savings⁵ indicate an average cost saving per patient per year of £1,478. If 25% of the 62,000 patients in England who received NHS provided TKR in 2023 received Apos instead this would save the NHS £36.5 million. Furthermore, for 25% of all TKR surgeries in 2023 this would lead to a carbon saving 3,033 tonnes of CO₂e⁶.

Treatment benefits of APOS

Aligns with best practice recommendations



The MedTech Funding Mandate (MTFM)⁷

The MTFM is an NHS England commitment for getting NICE-recommended cost-saving technology like Apos to patients quickly. It ensures commissioner funding for selected products, to make them available to patients. The Health Innovation Networks are responsible for delivering the MTFM by working with NHS providers and ICSs to support equitable provision of chosen technologies and help overcome barriers to adoption.

For more information contact: Dr Julian O'Kelly, Innovation Manager: iulian.okelly@nhs.net